酶稳定的GIP/xenin杂合肽可恢复GIP敏感性、增强β细胞功能并改善高脂喂养小鼠的血糖稳态
本研究在高脂喂养小鼠中评估了(DAla2)GIP/xenin-8-Gln杂合肽与亲本肽(DAla2)GIP和xenin-8-Gln的作用。杂合肽在体外增强胰岛素分泌,急性给药降低血糖并增加血浆胰岛素,每日两次给药21天使血糖恢复至瘦对照水平,并改善胰岛素敏感性、增加胰岛和β细胞面积。作者认为GIP/xenin杂合肽在2型糖尿病治疗方面具有明显潜力。
要点
- (DAla2)GIP/xenin-8-Gln在体外显著增强BRIN-BD11细胞胰岛素分泌。
- 高脂喂养小鼠每日两次给药21天,血糖恢复至瘦对照水平。
- 杂合肽增加胰岛和β细胞面积及胰腺胰岛素含量,与β细胞增殖增强和凋亡减少相关。
核心结论
- 这些研究突显了GIP/xenin杂合肽在2型糖尿病治疗方面的明显潜力。
研究设计与样本
- 研究先确认酶稳定性,在BRIN-BD11 β细胞中评估胰岛素分泌活性,随后在体内检查急性和持续性降糖及促胰岛素释放作用。
- 最后在高脂喂养小鼠中确定每日两次注射(DAla2)GIP/xenin-8-Gln的代谢获益。
主要发现
- 所有肽均显著增强胰腺克隆BRIN-BD11细胞的体外胰岛素分泌(p < 0.05至p < 0.001),xenin(尤其是GIP)相关信号通路对此作用重要。
- 给予(DAla2)GIP或(DAla2)GIP/xenin-8-Gln联合葡萄糖显著降低小鼠血糖并增加血浆胰岛素(p < 0.05),反应持续长达4 h。
- 所有处理均产生食欲抑制作用(p < 0.05),尤其是较高剂量250 nmol/kg的(DAla2)GIP/xenin-8-Gln和xenin-8-Gln。
- 高脂喂养小鼠每日两次给予(DAla2)GIP/xenin-8-Gln或(DAla2)GIP 21天,使循环血糖恢复至瘦对照水平;且(DAla2)GIP/xenin-8-Gln治疗在24 h血糖谱评估中显著降低血糖水平(p < 0.05)。
- 两种治疗方案对体重、能量摄入或循环胰岛素浓度均无影响,但均显著改善胰岛素敏感性(p < 0.001);(DAla2)GIP和(DAla2)GIP/xenin-8-Gln治疗还显著改善GIP介导的降糖(p < 0.05)和促胰岛素释放(p < 0.05至p < 0.01)效应。
临床怎么用
- 作者认为这些研究突显了GIP/xenin杂合肽在2型糖尿病治疗方面的明显潜力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Glucose-dependent insulinotropic polypeptide (GIP) and xenin, regulatory gut hormones secreted from enteroendocrine K cells, exert important effects on metabolism. In addition, xenin potentiates the biological actions of GIP. The present study assessed the actions and therapeutic utility of a (DAla2)GIP/xenin-8-Gln hybrid peptide, in comparison with the parent peptides (DAla2)GIP and xenin-8-Gln. METHODS: Following confirmation of enzymatic stability, insulin secretory activity of (DAla2)GIP/xenin-8-Gln was assessed in BRIN-BD11 beta cells. Acute and persistent glucose-lowering and insulin-releasing effects were then examined in vivo. Finally, the metabolic benefits of twice daily injection of (DAla2)GIP/xenin-8-Gln was determined in high-fat-fed mice. RESULTS: All peptides significantly (p < 0.05 to p < 0.001) enhanced in vitro insulin secretion from pancreatic clonal BRIN-BD11 cells, with xenin (and particularly GIP)-related signalling pathways, being important for this action. Administration of (DAla2)GIP or (DAla2)GIP/xenin-8-Gln in combination with glucose significantly (p < 0.05) lowered blood glucose and increased plasma insulin in mice, with a protracted response of up to 4 h. All treatments elicited appetite-suppressive effects (p < 0.05), particularly (DAla2)GIP/xenin-8-Gln and xenin-8-Gln at elevated doses of 250 nmol/kg. Twice-daily administration of (DAla2)GIP/xenin-8-Gln or (DAla2)GIP for 21 days to high-fat-fed mice returned circulating blood glucose to lean control levels. In addition, (DAla2)GIP/xenin-8-Gln treatment significantly (p < 0.05) reduced glycaemic levels during a 24 h glucose profile assessment. Neither of the treatment regimens had an effect on body weight, energy intake or circulating insulin concentrations. However, insulin sensitivity was significantly (p < 0.001) improved by both treatments. Interestingly, GIP-mediated glucose-lowering (p < 0.05) and insulin-releasing (p < 0.05 to p < 0.01) effects were substantially improved by (DAla2)GIP and (DAla2)GIP/xenin-8-Gln treatment. Pancreatic islet and beta cell area (p < 0.001), as well as pancreatic insulin content (p < 0.05), were augmented in (DAla2)GIP/xenin-8-Gln-treated mice, related to enhanced proliferation and decreased apoptosis of beta cells, whereas (DAla2)GIP evoked increases (p < 0.05 to p < 0.01) in islet number. CONCLUSIONS/INTERPRETATION: These studies highlight the clear potential of GIP/xenin hybrids for the treatment of type 2 diabetes.
引用
- Hasib A, Ng MT, Gault VA, et al. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice. Diabetologia. 2016. PMID: 28004148. doi:10.1007/s00125-016-4186-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。